.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Merck
McKinsey
Colorcon
QuintilesIMS
Teva
Johnson and Johnson
Chubb
Express Scripts
US Department of Justice

Generated: July 28, 2017

DrugPatentWatch Database Preview

CYCLOMYDRIL Drug Profile

« Back to Dashboard

What is the patent landscape for Cyclomydril, and what generic Cyclomydril alternatives are available?

Cyclomydril is a drug marketed by Novartis Pharms Corp and is included in one NDA.

The generic ingredient in CYCLOMYDRIL is cyclopentolate hydrochloride; phenylephrine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cyclopentolate hydrochloride; phenylephrine hydrochloride profile page.

Summary for Tradename: CYCLOMYDRIL

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list36
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CYCLOMYDRIL at DailyMed

Pharmacology for Tradename: CYCLOMYDRIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
CYCLOMYDRIL
cyclopentolate hydrochloride; phenylephrine hydrochloride
SOLUTION/DROPS;OPHTHALMIC084300-001Approved Prior to Jan 1, 1982RXNoYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Fuji
Moodys
Cipla
Chubb
UBS
Chinese Patent Office
Queensland Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot